GlassScriptPhysician profile
Kelley M Shaffer
NPI 1538782677
$4,467.59
in general payments reported to CMS, 2019-2025
34 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $477 · 2023: $711 · 2024: $1,295 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,255 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,255.06 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $611.12 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $525.09 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $432.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $429.39 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.30 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $222.46 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $214.34 | 2023-2025 | |
| Glaxosmithkline, LLC. | $180.65 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $169.97 | 2022-2025 | Rexulti |
| Abbott Laboratories | $159.03 | 2023-2025 | Freestyle Libre, Proclaim |
| Biohaven Pharmaceuticals, INC. | $124.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.49 | 2023-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $99.09 | 2021-2025 | |
| Esperion Therapeutics, INC. | $94.79 | 2021 | |
| Amgen INC. | $91.88 | 2021-2025 | Repatha, Otezla, Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $85.91 | 2025 | Zurzuvae |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.00 | 2021-2023 | Xifaxan |
| Antares Pharma, INC. | $69.51 | 2021-2025 | Xyosted |
| Lundbeck LLC | $66.77 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $64.92 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.97 | 2021-2023 | |
| Indivior INC. | $60.47 | 2021-2022 | |
| Exact Sciences Corporation | $54.92 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $32.47 | 2024 | Fanapt |
| Corium, LLC | $26.35 | 2024 | Azstarys |
| Dexcom, INC. | $22.43 | 2023 | Dexcom G6 Transmitter |
| Orexo US, INC. | $20.80 | 2021 | |
| Amarin Pharma, INC. | $18.32 | 2021 | |
| Dynavax Technologies Corporation | $17.09 | 2024 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $16.87 | 2023 | Quviviq |
| Impel Pharmaceuticals INC. | $15.99 | 2022 | |
| Seqirus USA INC | $15.98 | 2025 | Fluad, Flucelvax |
| Sumitomo Pharma America, INC. | $14.20 | 2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $13.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.